An observational study on 80,605 patients with HR+, HER2– breast cancer and node-negative or node-positive (up to 3) confirmed that patients with low Recurrence Score results with the the Oncotype DX® test have excellent clinical outcome when receiving hormone therapy alone [34]. Here, ERBB2 is linked to breast cancer.